Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial

BACKGROUND

In 2019, we reported the first efficacy and safety analysis of EUCROSS, a phase II trial investigating crizotinib in ROS1 fusion-positive lung cancer. At that time, overall survival (OS) was immature and the effect of crizotinib on intracranial disease control remained unclear. Here, we present the final analysis of OS, systemic and intracranial activity, and the impact of co-occurring aberrations.

MATERIALS AND METHODS

EUCROSS was a prospective, single-arm, phase II trial. The primary endpoint was best overall response rate (ORR) using RECIST 1.1. Secondary and exploratory endpoints were progression-free survival (PFS), OS, and efficacy in pre-defined subgroups.

RESULTS

Median OS of the intention-to-treat population (N = 34) was 54.8 months [95% confidence interval (CI) 20.3 months-not reached (NR); median follow-up 81.4 months] and median all-cause PFS of the response-evaluable population (N = 30) was 19.4 months (95% CI 10.1-32.2 months). Time on treatment was significantly correlated with OS (R = 0.82; P < 0.0001). Patients with co-occurring TP53 aberrations (28%) had a significantly shorter OS [hazard ratio (HR) 11; 95% CI 2.0-56.0; P = 0.006] and all-cause PFS (HR 4.2; 95% CI 1.2-15; P = 0.025). Patients with central nervous system (CNS) involvement at baseline (N = 6; 20%) had a numerically shorter median OS and all-cause PFS. Median intracranial PFS was 32.2 months (95% CI 23.7 months-NR) and the rate of isolated CNS progression was 24%.

CONCLUSIONS

Our final analysis proves the efficacy of crizotinib in ROS1-positive lung cancer, but also highlights the devastating impact of TP53 mutations on survival and treatment efficacy. Additionally, our data show that CNS disease control is durable and the risk of CNS progression while on crizotinib treatment is low.

Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling

T-cell prolymphocytic leukemia (T-PLL) is a poor-prognostic neoplasm. Differentiation stage and immune-effector functions of the underlying tumor cell are insufficiently characterized. Constitutive activation of the T-cell leukemia 1A (TCL1A) oncogene distinguishes the (pre)leukemic cell from regular postthymic T cells. We assessed activation-response patterns of the T-PLL lymphocyte and interrogated the modulatory impact by TCL1A. Immunophenotypic and gene expression profiles revealed a unique spectrum of memory-type differentiation of T-PLL with predominant central-memory stages and frequent noncanonical patterns. Virtually all T-PLL expressed a T-cell receptor (TCR) and/or CD28-coreceptor without overrepresentation of specific TCR clonotypes. The highly activated leukemic cells also revealed losses of negative-regulatory TCR coreceptors (eg, CTLA4). TCR stimulation of T-PLL cells evoked higher-than-normal cell-cycle transition and profiles of cytokine release that resembled those of normal memory T cells. More activated phenotypes and higher TCL1A correlated with inferior clinical outcomes. TCL1A was linked to the marked resistance of T-PLL to activation- and FAS-induced cell death. Enforced TCL1A enhanced phospho-activation of TCR kinases, second-messenger generation, and JAK/STAT or NFAT transcriptional responses. This reduced the input thresholds for IL-2 secretion in a sensitizer-like fashion. Mice of TCL1A-initiated protracted T-PLL development resembled such features. When equipped with epitope-defined TCRs or chimeric antigen receptors, these Lckpr-hTCL1Atg T cells gained a leukemogenic growth advantage in scenarios of receptor stimulation. Overall, we propose a model of T-PLL pathogenesis in which TCL1A enhances TCR signals and drives the accumulation of death-resistant memory-type cells that use amplified low-level stimulatory input, and whose loss of negative coregulators additionally maintains their activated state. Treatment rationales are provided by combined interception in TCR and survival signaling.

Virtual mono-energetic images and iterative image reconstruction: abdominal vessel imaging in the era of spectral detector CT

AIM

To compare the quality of virtual mono-energetic (VMI) and polychromatic images reconstructed with hybrid iterative (PCI_HIR) or model-based reconstruction (PCI_MBR) derived from dual-layer spectral detector computed tomography (SDCT) in arterial phase images to visualise the aorta and abdominal main branches.

MATERIAL AND METHODS

A retrospective review of 50 patients with abdominal arterial phase scans was undertaken. Attenuation, intraluminal noise, and signal-/contrast-to-noise ratio (S-/CNR) were assessed in the PCI_HIR, PCI_MBR and VMI_40keV, VMI_70keV, and VMI_100keV images. Contrast, noise, and visualization of soft-plaque, and macro-/micro-calcifications were scored in a blinded reading by two radiologists.

RESULTS

VMI_40keV yielded highest S-/CNR (p≤0.001). VMI_70keV and PCI_MBR showed comparable SNR (p≥0.999) and yielded higher SNR than PCI_HIR. VMI_70keV yielded higher CNR than PCI_HIR (p<0.001) and PCI_MBR (p<0.045). VMI_100keV yielded lowest CNR (p≤0.001) and SNR (p≥0.104). In the subjective analysis, VMI_40keV outperformed PCI_MBR for contrast and noise, PCI_MBR scored better than VMI_70keV, and the latter scored better than PCI_HIR for these categories (all p<0.001). PCI_MBR was superior for depiction of soft-plaque and micro-calcifications (p<0.001). VMI_100keV visualized micro-calcifications second best (p<0.001) and matched PCI_MBR for the depiction of macro-calcifications (p>0.999), while VMI_40keV scored second best for depiction of soft-plaque (p<0.020).

CONCLUSIONS

VMI_40keV and VMI_70keV yield better S-/CNR than PCI_HIR and PCI_MBR; however, PCI_MBR visualized arteriosclerotic plaques best, followed by VMI_40keV for depiction of soft-plaque and VMI_100keV for macro- and micro-calcification. Based on the present findings, PCI_MBR on conventional CT and VMI_40keV supplemented by VMI_100keV on SDCT are recommended for the diagnostic assessment of abdominal arteries.

[Image-guided, minimally invasive surgery and other local therapeutic procedures for primary liver tumors]

BACKGROUND

The incidence of primary liver tumors is rising. Modern minimally invasive, image-guided procedures offer a potentially curative therapy option.

OBJECTIVE

The aim of this study was to evaluate the multitude of image-guided minimally invasive procedures concerning their evidence-based effect on local tumor control and overall survival.

MATERIAL AND METHODS

A systematic search of MEDLINE focused on hepatocellular cancer, minimally invasive treatment, local ablative therapy, therapeutic stratification and comparative studies was performed.

RESULTS

The level of evidence varied greatly depending on the procedure used. The highest quality evidence including prospective randomized studies was found for radiofrequency ablation (RFA) of hepatocellular cancer. The RFA is superior with respect to local tumor control and overall survival in comparison to other ablative procedures. Prospective randomized studies comparing surgery and RFA showed diverging and contradictory results. Microwave ablation and robotic stereotactic irradiation showed sufficient potential in retrospective studies in comparison to RFA and surgery in order to confirm the techniques in randomized studies. There is only anecdotal evidence concerning high intensity focused ultrasound (HIFU) and irreversible electroporation. Percutaneous ethanol injection (PEI), cryoablation and laser-induced thermal therapy (LITT) were inferior techniques to RFA in most studies.

CONCLUSION

Minimally invasive resection and local ablative therapies based on structured imaging and image reporting can improve the prognosis of patients with hepatocellular cancer even in patients that exceed the BCLC 0/A stage.

[Radiological response assessment of modern immunotherapy using iRECIST]

CLINICAL/METHODICAL ISSUE

Modern immunotherapies in oncology show tumor response patterns differing from conventional chemotherapies including initial pseudo-progression.

STANDARD RADIOLOGICAL METHODS

Response evaluation criteria in solid tumors (RECIST 1.1) represent the currently most used response criteria for conventional chemotherapy of solid tumors. However, atypical response patterns of immunotherapies are not correctly classified using RECIST 1.1 so that the effectiveness is also incorrectly interpreted.

METHODICAL INNOVATIONS

In order to correctly interpret these atypical response patterns, special immune-related response criteria in solid tumors (iRECIST) have been published. In contrast to RECIST 1.1 according to iRECIST an initially unconfirmed progressive disease (iUPD) requires confirmation (iCPD) in clinically stable patients by subsequent control imaging after 4-8 weeks. New lesions are separately assessed within iRECIST.

PERFORMANCE

The iRECIST procedure allows a standardized objective assessment of a possible pseudo-progression which can occur in up to 10% of cases depending on the immunomodulating drug and tumor entity.

ACHIEVEMENTS

In principle, iRECIST was developed only for usage in trials testing modern immunotherapeutics.

PRACTICAL RECOMMENDATIONS

The iRECIST procedure might also be helpful as an additional objective response criterium for clinical treatment decisions, taking the limitations into account.

Assessment of arterially hyper-enhancing liver lesions using virtual monoenergetic images from spectral detector CT: phantom and patient experience

PURPOSE

To investigate a benefit from virtual monoenergetic reconstructions (VMIs) for assessment of arterially hyper-enhancing liver lesions in phantom and patients and to compare hybrid-iterative and spectral image reconstructions of conventional images (CI-IR and CI-SR).

METHODS

All imaging was performed on a SDCT (Philips Healthcare, Best, The Netherlands). Images of a non-anthropomorphic phantom with a lesion-mimicking insert (containing iodine in water solution) and arterial-phase images from contrast-enhanced patient examinations were evaluated. VMIs (40-200 keV, 10 keV increment), CI-IR, and CI-SR were reconstructed using different strengths of image denoising. ROIs were placed in lesions, liver/matrix, muscle; signal-to-noise, contrast-to-noise, and lesion-to-liver ratios (SNR, CNR, and LLR) were calculated. Qualitatively, 40, 70, and 110 keV and CI images were assessed by two radiologists on five-point Likert scales regarding overall image quality, lesion assessment, and noise.

RESULTS

In phantoms, SNR was increased threefold by VMI_40keV compared with CI-IR/SR (5.8 ± 1.1 vs. 18.8 ± 2.2, p ≤ 0.001), while no difference was found between CI-IR and CI-SR (p = 1). Denoising was capable of noise reduction by 40%. In total, 20 patients exhibiting 51 liver lesions were assessed. Attenuation was the highest in VMI_40keV, while image noise was comparable to CI-IR resulting in a threefold increase of CNR/LLR (CI-IR 1.3 ± 0.8/4.4 ± 2.0, VMI_40keV: 3.8 ± 2.7/14.2 ± 7.5, p ≤ 0.001). Subjective lesion delineation was the best in VMI_40keV image (p ≤ 0.01), which also provided the lowest perceptible noise and the best overall image quality.

CONCLUSIONS

VMIs improve assessment of arterially hyper-enhancing liver lesions since they increase lesion contrast while maintaining low image noise throughout the entire keV spectrum. These data suggest that to consider VMI screening after arterially hyper-enhancing liver lesions.

Investigation of umbilical venous vessels anatomy and diameters as a guideline for catheter placement in newborns

Umbilical cord catheters (UCC) are important for the primary care of critically ill newborns. To analyze anatomical variations of the umbilical vein (UV) and its further course, we performed abdominal spiral-CT examinations on stillborns. The aim of the study was to explore the high incidence of mal-positioned UCCs and to improve their positioning. Eighteen stillborns were investigated (29.2 weeks ± 6.7 weeks (IQR)). CTs were performed using either air or contrast medium injection into the UV. We measured the diameter at the narrowest points of (i) the umbilical vein, (ii) the segmental portal vein, (iii) the left portal vein, (iv) the umbilical recess, and (v) the ductus venosus. The branching angles between (a) the umbilical vein and intrahepatic veins and (b) the ductus venosus and umbilical recess were measured. The diameter of the UV increases from 3.4 to 11 mm (median [IQR]:4.6 mm [4.2-6.9]: r²  = 0.64). The left portal vein has a larger diameter (3.6 mm [2.6-4.55]; r²  = 0.43) than the left segmental portal vein (2.3 mm [1.8-2.75]; r²  = 0.23). The diameter of the ductus venosus (2.5 mm [1.6-3.4]; r²  = 0.59) is half that of the umbilical recess (5.1 mm [3.3-6.2]; r²  = 0.43). The most obtuse angle is formed by the junction between the umbilical recess and ductus venosus (151° [133-159]; r²  = 0.001). The branch angle from the outgoing UV into the left portal vein is more obtuse (128° [123-144]; r²  = 0.0001) than that of the segmental portal vein (115° [105-119]; r²  = 0.0001). To avoid mal-positioning, our data suggest the use of a soft catheter. The UV and its extensions are wide enough to admit a 4 Fr. catheter without complete obstruction. Clin. Anat. 31:269-274, 2018. © 2017 Wiley Periodicals, Inc.

[Modern magnetic resonance imaging of the liver]

Magnetic resonance imaging (MRI) of the liver has become an essential tool in the radiological diagnostics of both focal and diffuse diseases of the liver and is subject to constant change due to technological progress. Recently, important improvements could be achieved by innovations regarding MR hardware, sequences and postprocessing methods. The diagnostic spectrum of MRI could be broadened particularly due to new examination sequences, while at the same time scanning time could be shortened and image quality has been improved. The aim of this article is to explain both the technological background and the clinical application of recent MR sequence developments and to present the scope of a modern MRI protocol for the liver.

Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany

We report the first culture-proven case of invasive aspergillosis (IA) caused by azole-resistant Aspergillus fumigatus in a patient with acute myeloid leukaemia in Germany. IA presented as breakthrough infection under posaconazole prophylaxis. Analysis of the resistance mechanism revealed the TR/L98H mutation in the cyp51A gene, which indicates an environmental origin of the strain. This case underscores the need for monitoring azole resistance in Aspergillus spp. and for routine susceptibility testing of moulds.

Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany

We report the first culture-proven case of invasive aspergillosis (IA) caused by azole-resistant Aspergillus fumigatus in a patient with acute myeloid leukaemia in Germany. IA presented as breakthrough infection under posaconazole prophylaxis. Analysis of the resistance mechanism revealed the TR/L98H mutation in the cyp51A gene, which indicates an environmental origin of the strain. This case underscores the need for monitoring azole resistance in Aspergillus spp. and for routine susceptibility testing of moulds.

Current role and future perspective of MRI for diagnosis and characterization of renal cell carcinoma

During the past years, magnetic resonance imaging (MRI) has been established as a reliable method for examination of the kidneys. Modern MRI systems enable to visualize renal masses with a high spatial resolution. This enables not only to differentiate between benign lesions and renal cancer but also to define the tumor stage with high accuracy. The impact of a precise preoperative staging has increased significantly due to stage adapted therapy approaches such as nephron sparing surgery or local ablative techniques (e.g. radiofrequency ablation). Tumor-related infiltration of the renal pelvis, infiltration of the perinephric fat or a tumor thrombus within the inferior caval vein has to be diagnosed with high accuracy to enable these stage adapted treatment regimens. This article introduces into clinically established "morphologic" MRI techniques for diagnosis and staging of renal cell carcinoma (RCC). Besides detection and staging of kidney cancer, the recent development of molecularly targeted therapies in patients with metastatic or non-operable tumors has led to novel diagnostic demands. To evaluate treatment efficiency, more information than just tumor morphology should be provided. Functional imaging techniques including dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), arterial spin labeling (ASL) and MR-spectroscopy are being investigated in preclinical and clinical trials. While some new techniques have shown promising results for a broad clinical application, others seem to be suited for dedicated questions only.